GlassScriptPhysician profile
Brian David Hess
NPI 1124514609
$7,841.17
in general payments reported to CMS, 2019-2025
10 companies · $7,388 in 2025
The $7,388 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $141 · 2021: $83.11 · 2025: $7,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,460 · Consulting Fee: $910 · Travel and Lodging: $896 · Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,460.00 |
| Consulting Fee | $910.00 |
| Travel and Lodging | $895.81 |
| Food and Beverage | $121.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $7,387.80 | 2025 | |
| Janssen Pharmaceuticals, INC | $195.02 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $97.15 | 2019-2020 | |
| Janssen Biotech, INC. | $39.84 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $33.62 | 2019 | |
| Pfizer INC. | $20.59 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.26 | 2019 | |
| Amgen INC. | $17.32 | 2021 | |
| Corcept Therapeutics | $16.95 | 2021 | |
| Gilead Sciences, INC. | $14.62 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.